FDA Accepts Supplement for Romvimza (Vimselitinib) by Deciphera Pharmaceuticals
The FDA has accepted a supplemental NDA for Romvimza (Vimselitinib) from Deciphera Pharmaceuticals.
Company
Pharmaceutical intelligence for Deciphera Pharmaceuticals with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.